Label Changes for:
DepoDur (morphine sulfate extended-release) liposome injection
Changes have been made to the PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- September 2009
- revised to include statement to reinforce that DepoDur dosing will need to be adjusted in the elderly and other risk groups taking into account the patient's age, body mass, physical status, prior experience with opiate analgesics, risk factors for respiratory depression, and medications to be co-administered before or during surgery
- revised to include pharmacokinetic interaction with respect to DepoDur and therapeutic doses of local anesthetic bupivacaine HCI